Standout Papers

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherap... 2009 2026 2014 2020 550
  1. Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma (2009)
    Richard Piekarz, Robin Frye et al. Journal of Clinical Oncology
  2. Antibody–drug conjugates for cancer (2019)
    Cindy H. Chau, Patricia S. Steeg et al. The Lancet

Immediate Impact

9 by Nobel laureates 11 from Science/Nature 70 standout
Sub-graph 1 of 21

Citing Papers

Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
2023 Standout
Microbiota and maintenance of skin barrier function
2022 StandoutScience

Works of William D. Figg being referenced

Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics
2021
Resistance to second-generation androgen receptor antagonists in prostate cancer
2021

Author Peers

Author Last Decade Papers Cites
William D. Figg 9855 11342 4342 599 24.6k
Ravi Salgia 10406 12218 8256 618 26.9k
James H. Doroshow 10768 12232 3580 571 25.0k
Mark J. Ratain 10113 9035 4281 528 22.7k
Herbert M. Pinedo 15681 11909 3825 569 29.4k
Patricia LoRusso 10965 10660 4274 560 21.3k
Hong Wang 6712 9697 3272 714 24.5k
Ting‐Chao Chou 7854 13621 2184 342 28.3k
Richard Greil 10588 5190 3989 716 19.5k
Naoto T. Ueno 10744 5453 3626 537 19.9k
Edward A. Sausville 11549 19041 2801 325 30.4k

All Works

Loading papers...

Rankless by CCL
2026